Sensitivity Analysis of Genes Related to Prognosis of Advanced Non-small Cell Lung Cancer to Cisplatin and Paclitaxel

OBJECTIVE To explore the correlation between the expression of prognostic genes in advanced non-small cell lung cancer and the sensitivity changes of the paclitaxel and cisplatin of chemotherapy drugs by using bioinformatics methods. METHODS Download the gene expression profile and corresponding clinical information of non-small cell carcinoma cases through the the cancer genome atlas. Screen hub gene between normal tissue samples and cancer tissue samples. Weighted gene co-expression network analysis determined pivot genes related to clinical stage, and univariate Cox analysis determined differential gene related to prognosis. Download genomics of drug sensitivity in cancer to integrate the expression data of non-small cell lung cancer cell line and the genetic data of cell line and drug response, to analyze the correlation between the differential gene expression related to the prognosis and clinical stage of non-small cell lung cancer to the sensitivity of paclitaxel and cisplatin drugs. RESULTS Four genes were identified to be related to paclitaxel sensitivity reaction; eight genes were related to cisplatin sensitivity reaction. Changes in the expression levels of SPATS2 and CA3 were correlated with the sensitivity responses of paclitaxel and cisplatin. Increased expression levels of CA3 increased resistance to paclitaxel and cisplatin. Increased expression levels of SPATS2 increased sensitivity to paclitaxel and cisplatin. CONCLUSION The increased expression of CA3 and SPATS2 genes in patients with advanced non-small cell lung cancer have enhanced drug resistance and increased sensitivity to paclitaxel and cisplatin, respectively.